3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Conditions
Hereditary Sensory and Autonomic Neuropathies
3
Squamous Cell Carcinoma of Head and Neck
1
Recurrence
1
Prostatic Neoplasms
1
Neoplasms
1
Glioblastoma
1
Colorectal Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma
1
Interventions
Carboplatin
27
Paclitaxel
23
Cisplatin
22
Gemcitabine
17
pembrolizumab
15
Fluorouracil
9
Pemetrexed
8
Everolimus
8
Docetaxel
8
Cetuximab
8
Radiotherapy, Intensity-Modulated
7
Radiotherapy
7
130-nm albumin-bound paclitaxel
7
Sorafenib
6
Nivolumab
6
Bevacizumab
6
Axitinib
6
epothilone B
5
Sunitinib
5
Radiation
5
Panitumumab
5
Cyclophosphamide
5
trebananib
4
reolysin
4
padeliporfin
4
lenvatinib
4
Irinotecan
4
Gefitinib
4
vosaroxin
3
volociximab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Carcinoma
×
PX-866
×
Clear all
NCT00726583
2018-05-17
Phase I Trial of Oral PX-866
Seagen Inc.
Phase 1
Completed
90 enrolled